These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905 [TBL] [Abstract][Full Text] [Related]
4. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859 [TBL] [Abstract][Full Text] [Related]
5. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Tahara A; Takasu T Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293 [TBL] [Abstract][Full Text] [Related]
6. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice. Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M Vascul Pharmacol; 2020 Jan; 124():106632. PubMed ID: 31759113 [TBL] [Abstract][Full Text] [Related]
7. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275 [TBL] [Abstract][Full Text] [Related]
8. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution. Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936 [TBL] [Abstract][Full Text] [Related]
9. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. Ohkura T World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250 [TBL] [Abstract][Full Text] [Related]
11. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845 [TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Tahara A; Takasu T Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258 [TBL] [Abstract][Full Text] [Related]
13. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. Tahara A; Kondo Y; Takasu T; Tomiyama H Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338 [TBL] [Abstract][Full Text] [Related]
14. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Tahara A; Takasu T Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076 [TBL] [Abstract][Full Text] [Related]
15. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351 [TBL] [Abstract][Full Text] [Related]
16. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. Zhang MH; Feng L; Zhu MM; Gu JF; Jiang J; Cheng XD; Ding SM; Wu C; Jia XB J Ethnopharmacol; 2014; 151(1):591-600. PubMed ID: 24269777 [TBL] [Abstract][Full Text] [Related]
17. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353 [TBL] [Abstract][Full Text] [Related]